Amplia Enters Into Second Agreement With Korean Drug Screening Company Next&Bio
ReutersDec 19, 2025 2:25 PM
Dec 19 (Reuters) - Amplia Therapeutics Ltd ATX.AX:
AMPLIA ENTERS INTO SECOND AGREEMENT WITH KOREAN SPECIALIST DRUG SCREENING COMPANY NEXT&BIO TO EXPLORE COMBINATION THERAPY WITH FAK INHIBITOR AND KRAS INHIBITORS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Nvidia Strikes Technology Licensing Deal with Groq — Why Is It Buying the Tech Instead of the Company?
TradingKey - On December 24, local time, Groq, a U.S. AI chip startup, announced on its official website that it had reached a non-exclusive technology licensing agreement with NVIDIA.TradingKey
10 hours ago
TradingKey 2025 Markets Recap & Outlook | Global Central Banks 2026 amid Post‑Easing Recovery and Diverging Paths
TradingKey - In 2025, major global central banks will largely maintain an accommodative stance, but the policy pace will decelerate notably. As the easing cycle draws to a close, how will global monetary policy evolve?TradingKey
12 hours ago
Ripple Price Prediction: Why Is XRP Price Falling? Can It Rise to $10 in the Future?
XRP has weakened this year due to profit-taking, capital outflows, and its correlation with Bitcoin. Despite support from potential spot ETFs and positive regulatory developments, significant market divergence, liquidity uncertainty, and macroeconomic uncertainty remain high. XRP's price is likely tTradingKey
Wed, Dec 24
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Tradingkey
